Table 1 Demographic, clinical, and laboratory characteristics of the studied AML patients
From: Reductive regulation of BECN1 gene in adult Egyptian patients with do novo AML
Parameter | AML patients (total no. = 50) |
|---|---|
Sex [n (%)] | |
Females | 28 (56.0%) |
Males | 22 (44.0%) |
Age (years) | |
Mean ± SD | (51.56 ± 20.17) |
Clinical data [n (%)] | |
Fever | 11(22.0%) |
Hepatomegaly | 19(38.0%) |
Splenomegaly | 19(38.0%) |
Lymphadenopathy | 4(8.0%) |
TLC (x109/L) (Median—IQR) | 54.8 (22.3–76.4) |
Hb (g/dl) (Mean ± SD) | (8.09 ± 2.01) |
PLT (x109/L) (Median—IQR) | 33 (24–68) |
PB blasts (%) (Mean ± SD) | (56.96 ± 23.43) |
BM blasts (%) (Mean ± SD) | (75.68 ± 20.83) |
Immunophenotyping [n (%)] | |
CD34 + | 33 (66.0%) |
CD117 + | 32 (64.0%) |
HLA-DR + | 43 (86.0%) |
FAB subtypes [n (%)] | |
M0 | 5 (10.0%) |
M1 | 10 (20.0%) |
M2 | 20 (40.0%) |
M3 | 5 (10.0%) |
M4 | 7 (14.0%) |
M5 | 3(6.0%) |
Molecular abnormalities [n (%)] | |
Wild type NPM1 | 5 (10.0%) |
Mutated NPM1 and FLT3-ITD | 2 (4.0%) |
FLT3-ITD mutation | 14 (28.0%) |
c-KIT mutation | 8 (16.0%) |
Cytogenetic risk groups [n (%)] | |
Favourable | 11 (22.0%) |
Intermediate | 10 (20.0%) |
Adverse | 29 (58.0%) |
Response to induction therapy (D28) [n (%)] | |
Responders | 15 (30.0%) |
Non- responders | 35 (70.0%) |